Barry Diller's $18 Billion Bid for MGM Resorts: Analyzing the Market Impact
Barry Diller's $18 billion proposal for MGM Resorts at $48.30 per share could reshape the gaming industry landscape.
UAW Strike Disrupts GM's Pickup Truck Production: What Investors Need to Know
The UAW strike threatens GM's production schedule, raising concerns for investors about potential quarterly earnings.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
AI Momentum Fuels Wall Street to Record Highs Despite Geopolitical Concerns
Wall Street is buoyed by AI advancements from Nvidia and Meta, pushing markets to new highs amid geopolitical tensions.
AbbVie's FDA Approval of DECNUPAZ: A New Era for Rare Blood Cancer Treatment
AbbVie secures FDA approval for DECNUPAZ, marking a pivotal moment in its oncology pipeline and stock performance.
Parex Resources: A Major Acquisition Makes It Colombia's Oil Leader
Parex Resources solidifies its position in Colombia's oil market with a significant acquisition, but risks remain.
Weatherford's Strategic $151 Million Acquisition of NCS Multistage
Weatherford is set to acquire NCS Multistage for $151 million, enhancing its position in the energy sector.
Motorola Solutions' $1.5 Billion Bet on Counter-Drone Technology
Motorola Solutions is acquiring D-Fend Solutions for $1.5 billion, marking a key move into the defense sector.
MGM Resorts: An $18 Billion Takeover Bid and Its Implications for Investors
Barry Diller's People Inc. proposes an $18 billion bid for MGM Resorts, stirring market speculation and investor interes…
International Flavors & Fragrances: Strategic Divestiture of Food Ingredients Business
IFF's $4.3B sale of its Food Ingredients business signals a sharpened focus on core operations amidst a vibrant private …
Talkspace's Path Forward: Major Acquisition by Universal Health Services Approved
Talkspace's acquisition by UHS marks a strategic shift in digital mental health services.
Replimune's 40% Surge: A New Hope for Melanoma Treatment?
Replimune's shares soared 40% after FDA's resubmission agreement for its melanoma drug, signaling potential regulatory s…